Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics

Enzalutamide, an antiandrogen, is approved for therapy of castration resistant prostate cancer. Clinical applications have shown that approximately 30% of patients acquire resistance after a short period of treatment. However, the molecular mechanisms underlying this resistance is not completely und...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Mol Sci
Päätekijät: Verma, Shiv, Shankar, Eswar, Kalayci, F. Naz Cemre, Mukunda, Amrita, Alassfar, Malek, Singh, Vaibhav, Chan, E. Ricky, MacLennan, Gregory T., Gupta, Sanjay
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7765584/
https://ncbi.nlm.nih.gov/pubmed/33339129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21249568
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia